Your selections:
Pharmaco-phosphoproteomic analysis of cancer-associated KIT mutations D816V and V560G
- Murray, Heather C., Miller, Kasey, Dun, Matthew D., Verrills, Nicole M.
Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition
- Islam, Saiful, Rahaman, Muhammed H., Yu, Mingfeng, Noll, Benjamin, Martin, Jennifer H., Wang, Shudong, Head, Richard
Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia
- Murray, Heather C., Miller, Kasey, Brzozowski, Joshua S., Kahl, Richard G. S., Smith, Nathan D., Humphrey, Sean J., Dun, Matthew D., Verrills, Nicole M.
Targeting reactive oxygen species for the treatment of acute myeloid leukaemia
- McCaughan, Georgia, Di Ciaccio, Pietro, Ross, David M., Mulligan, Stephen, Trotman, Judith, Dickinson, Michael, Quach, Hang, Choi, Phillip, Polizzotto, Mark N., Tam, Constantine S., Ho, P. Joy, Ku, Matthew, Ananda-Rajah, Michelle, Gregory, Gareth, Gangatharan, S, Hapgood, G, Cochrane, T, Cheah, C, Gibbs, S, Wei, A, Johnston, A, Greenwood, M, Prince, HM, Gilroy, Nicole, Latimer, M, Berkahn, L, Wight, J, Armytage, T, Hamad, N, MacIntyre, Raina, Teh, Benjamin, Weinkove, Robert, Curnow, Jennifer, Szer, Jeff, Enjeti, Anoop K.
Parp inhibitors and haematological malignancies—friend or foe?
- Skelding, Kathryn A., Lincz, Lisa F.
- Clarke, William A., Chatelut, Etienne, Fotoohi, Alan K., Larson, Richard A., Martin, Jennifer H., Mathijssen, Ron H. J., Salamone, Salvatore J.
Development of novel PP2A activators for use in the treatment of acute myeloid leukaemia
- Toop, Hamish D., Dun, Matthew D., Ross, Bryony K., Flanagan, Hayley M., Verrills, Nicole M., Morris, Jonathan C.
- Verrills, Nicole M., Liem, Natalia L., Liaw, Tracey Y. E., Hood, Brian D., Lock, Richard B., Kavallaris, Maria
Are you sure you would like to clear your session, including search history and login status?